Under the terms of the agreement, Lupin will receive an up-front payment of $15mn and potential commercial milestones together with an equal share in net profits of the product.
Biocon has said that it retains its economic interest in this arrangement vis-a-vis Mylan in accordance with its existing collaboration agreement and would benefit from the opportunity to accelerate commercialization of Enbrel. Biocon’s Enbrel biosimilar is at pre-clinical levels and far from the approval stage.
This is second such arrangement in which its partner Mylan has partnered with a differet pharma company to acclerate the biosimilar commercialization.
The first was Mylan entered with Fujifilm for Humira biosimilar in April 2018. Biocon will also receive economic benefit through this collaboration.